We crystallise small-molecule drugs in low Earth orbit — where crystals grow more uniform and more stable than Earth can reliably achieve — and deliver the material back to our pharmaceutical partners.
Most drugs are crystals, and the crystal form decides how well a drug works. For a stubborn minority of molecules, the best-performing form is unstable or inconsistent on Earth.
Why orbit changes this →Gravity drives convection and sedimentation — the hidden sources of crystal defects. In orbit, crystals grow by pure diffusion: larger, more uniform, with fewer defects.
Already demonstrated in orbit →A standard API supply relationship: hand over a molecule, receive better material. The entire space operation is ours, end to end.
How the platform works →A superior crystal form creates value at two moments in a drug's life.
When the form that works best is metastable, or won't stay consistent batch to batch, the route to market closes. Orbital crystallisation can reopen it — better dissolution and bioavailability, reduced variability, a stronger manufacturing position.
A differentiated, patentable crystal form a generic cannot copy gives prescribers a clinical reason to stay with the brand — and the owner a way to hold market share past the cliff.
Orbital pharmaceutical manufacturing has just turned commercial. Zero Gravity Works is building the European play on top of it — from Milan, supported by ESA BIC and an advisory network across eight universities.
Write to info [at] zerogravityworks [dot] com